Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.25 USD | -3.68% | -3.35% | -34.43% |
May. 31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
May. 24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.43% | 4.95B | |
-2.29% | 89.38B | |
-3.95% | 37.92B | |
-13.07% | 32.04B | |
+63.05% | 26.03B | |
-22.14% | 14.14B | |
-7.96% | 12.88B | |
-9.33% | 11.77B | |
-46.33% | 10.85B | |
+5.77% | 8.92B |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals Enters Into Senior Secured Credit Facility With Sixth Street